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Psychoactive substances such as the ring substituted phenylethylamine 3,4-
methylenedioxymethamphetamine (MDMA; “ecstasy”) are widely used in recreational settings. 
Additionally, recent research highlights substance-assisted psychotherapy as potential new 
effective treatment for various psychiatric disorders, e.g. post-traumatic stress disorder (PTSD). 
MDMA releases and inhibits the uptake of serotonin (5-HT), norepinephrine (NE), and dopamine 
(DA) via an interaction with the respective monoamine transporter. Additionally, MDMA 
increases blood levels of the hormone oxytocin. Through these mechanisms, MDMA produces 
autonomic and distinct psychological effects such as increased empathy and sociability - effects 
that may prove to be helpful in psychotherapy. Despite the widespread recreational use and 
growing interest in using MDMA for medical purposes, interindividual differences in the response 
to MDMA are not elucidated. Genetic variants, such as single-nucleotide polymorphisms (SNPs) 
may influence the individual effects of MDMA. To address this matter, we used a uniquely large 
population of up to 166 subjects assembled from pooled but highly standardized phase I MDMA 
studies and conducted in-depth analyses on the clinical safety and on the influence of different 
genetic variations on the effects of MDMA.  
The first part of the present thesis was to evaluate the clinical safety pharmacology of 
single-dose administrations of 75 or 125 mg of MDMA. In up to a third of the subjects, 
administration of MDMA showed notable increases in maximum systolic blood pressure (>160 
mmHg), heart rate (>100 bpm), and body temperature (>38 °C). Those effects on autonomic 
measures were significantly greater in subjects receiving 125 mg of MDMA. Acute and subacute 
adverse reactions such as headache, bruxism or lack of appetite were also dose-dependent and 
more frequent in women than men. However, no extreme outliers were observed, and the use of 
MDMA was considered as safe in controlled clinical settings. Nevertheless, we suggest a lower 
therapeutic dose for women. Due to the sympathomimetic stimulation, risks of MDMA might be 
higher in patients with cardiovascular diseases and should be further investigated in psychiatric 
patients with comorbidities. 
In the second part of this thesis focus was laid on the identification of pharmacogenetic 
roles in the effects of MDMA. Specifically, the influence of genetic variants within genes coding 
for relevant cytochromes P450 (CYPs), and pharmacodynamic targets such as the 5-HT, NE, and 
DA system, and oxytocin receptors, on the response to MDMA was tested. We found that CYP2D6 
poor metabolizers (PMs) exhibited increased plasma levels of MDMA, leading to accelerated 
cardiovascular and psychostimulant responses to acute MDMA administration. Polymorphisms 
in CYP2D6, CYP1A2, CYP2C19, and CYP2B6 altered the metabolism of MDMA to 3,4-
methylenedioxyamphetamine (MDA), but showed no clinical relevance. In additional analyses, 
moderating effects for MDMA-induced feelings of trust and desire for company between 
variations of an oxytocin receptor single nucleotide polymorphism (SNP OXTR rs1042778) were 
shown.  
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To our knowledge, investigations assessing the influence of the monoamine system gene 
variations on the effects of MDMA were mostly the first on this matter. Subsequently, results had 
to be rigorously corrected for statistical errors and tested for specific hypothesis. Most of the 
tested genetic polymorphisms in the 5-HT (7 SNPs and 1 repeat polymorphism), NE (5 SNPs), 
and DA (10 SNPs and 1 repeat polymorphism) systems did not alter the effects of MDMA when 
adjusting for multiple comparisons. Only SNPs in the NE transporter gene SLC6A2 (rs1861647, 
rs2242446, and rs36029) significantly altered the acute MDMA-induced cardiovascular response.  
In summary, apart from variations within CYPs, genetic polymorphisms seem to play a 
subordinate role in the acute MDMA effects and are unlikely to sum up all interindividual 
variations. 
Results from the present thesis showed that MDMA was overall safe and well-tolerated 
with only moderate adverse effects in a clinical setting. Furthermore, pharmacogenetic analysis 
highlighted possible relevant genetic variations for the pharmacokinetic and pharmacodynamics 
effects of MDMA and point out targets of interest, which can define the scope of future studies 
with MDMA.  
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1.1. History & Classification of MDMA 
The synthetic amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA) is 
commonly known as the main compound in the recreational drug “ecstasy”. According to the 
United Nations drug report, up to 40 million people between 15 – 64 years had used “ecstasy” in 
the past year worldwide. Prevalence rates are especially high in Australia, North America, and 
Western and Central Europe with 2.2%, 0.9%, and 0.9%, respectively (United Nations Office On 
Drugs And Crime, 2019). In 2016, a study in Switzerland showed that Swiss people over 15 years 
had a life time prevalence of “ecstasy” use of 3.9% with a maximum of 9.7% in the population 
between 25-34 years (Gmel G., 2017). 
MDMA was first synthesized 1912 and patented 1914 by the pharmaceutical company 
Merck. It was issued as an appetite suppressant but never released commercially (Green et al., 
1995; Benzenhofer and Passie, 2006). In the 1950ies it was shortly tested by the US military as 
“truth serum”, before the substance was introduced in psychotherapy in the late 1970ies 
(Benzenhofer and Passie, 2006). MDMA effects are known on one side to reduce fear, negative 
affect, and defensiveness, and on the other side to promote relaxation, emotional sensitivity, and 
empathy (Greer and Strassman, 1985; Grinspoon and Bakalar, 1986; Shulgin, 1986; Doblin, 
2002). Psychotherapists saw a great potential in these facilitating effects for therapeutic 
communication. The effects of MDMA were clearly distinguished from the stimulant class of the 
amphetamines and therefore classified as a new psychoactive substance class called the 
“entactogens” (Nichols, 1986). MDMA was not limited to the therapeutic setting and gained 
popularity under the name “ecstasy” in the new up-coming “rave” movement (Schwartz and 
Miller, 1997). However, the US government declared MDMA a drug of abuse and it was thereafter 
banned from most of the United Nations members in 1985 (Saunders and Walder, 1994). Despite 
the global ban, researchers and psychiatrist in Switzerland were periodically still permitted to use 
illegal substances under certain strict circumstances. In recent years, the research with MDMA 
and its therapeutic potential experienced also a revival in the US (Oehen et al., 2013; Mithoefer et 
al., 2016; Mithoefer et al., 2018). In 2018, two phase III trials started in the US with the goal of 
turning MDMA into a medically used substance for the assisted treatment of chronic post-
traumatic stress disorder (PTSD; Mithoefer et al., 2019). 
  
Introduction 
 
18 
 
1.2. Pharmacology of MDMA 
The onset of the acute effects of MDMA after oral administration is at a mean time of 33 
minutes after oral intake and reaches peak effects after 1.6 h. The mean effect duration is lasting 
4.2 h (Vizeli and Liechti, 2017). As all phenethylamines, MDMA contains a chiral center as it can 
form two enantiomers. The S-MDMA isoform is described to be more pharmacologically active 
than the R-MDMA (Pizarro et al., 2004). As main mechanism of action, MDMA interacts with 
multiple neurotransmitter systems causing an indirect acute efflux of presynaptic monoamine 
transmitters such as serotonin (5-HT), norepinephrine (NE), and dopamine (DA) into the 
synaptic cleft. This rapid release is triggered by an interaction on the monoamine transporter side. 
MDMA implies a reverse of the monoamine reuptake-carrier (Berger et al., 1992; Rudnick and 
Wall, 1992). The most potent affinity to monoamine transporters is shown for the NE transporter 
(NET; IC50: 0.447 µM), followed by the affinity to the 5-HT transporter (SERT; IC50: 1.36 µM), 
and 10 times weaker for the DA transporter (DAT; IC50: 17 µM; Simmler et al., 2013). Less 
important mechanisms of action might lie in the weak affinity of MDMA to 5-HT2 -, α2-adrenergic, 
M1-muscarinic, and H1-histamine receptors and the small inhibition of the monoamine oxidase 
enzyme (MAO; Battaglia et al., 1988; Green et al., 1995; Liechti and Vollenweider, 2000a; b; 2001; 
Hysek et al., 2012a). The typical acute psychotropic effects of MDMA including feelings of well-
being, trust, and euphoria are a result of the differential release of the aforementioned 
neurotransmitters (Liechti et al., 2000a; Hysek et al., 2011; Hysek et al., 2012d). Further, MDMA 
produces a rise in oxytocin plasma levels (Thompson et al., 2007; Dumont et al., 2009; Hysek et 
al., 2014a; Francis et al., 2016). The peptide hormone oxytocin is known to play a key role in 
regulating emotion processing and social behavior (Neumann, 2008; Meyer-Lindenberg et al., 
2011; Kuypers et al., 2014). Due to enhancement of emotional empathy and prosocial behavior, 
MDMA is called an “entactogen” or “empathogen” (Nichols, 1986; Hysek et al., 2014a). However, 
whether oxytocin is a substantial mediator of the effects of MDMA in humans is inconclusive 
(Kuypers et al., 2014). Studies have assessed the effects of MDMA on emotion recognition relating 
to the cognitive aspects of empathy (Bedi et al., 2009; Hysek et al., 2012b). MDMA selectively 
impaired the recognition of negative emotions, while other stimulants such as methylphenidate 
enhanced the recognition of emotions regardless of the valence (Schmid et al., 2014; Wardle and 
de Wit, 2014; Dolder et al., 2018; Schmidt et al., 2018). In clinical studies, subjective effects of 
MDMA are mostly perceived as positive, with minimal bad drug effects (Dolder et al., 2018; 
Figure 1). Women experienced more overall drug effects but seem also more prone to negative 
drug experiences under MDMA than men (Liechti et al., 2001a). 
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A single dose of 125 mg of MDMA increases systolic (SBP) and diastolic (DBP) blood 
pressure (Figure 2; Dolder et al., 2018), but also heart rate and body temperature compared to 
placebo (Liechti et al., 2001a; Dolder et al., 2018). In a placebo-controlled double-blind study in 
8 healthy adults, mean heart rate was elevated by 30 beats/min (bpm) and the cardiac output by 
2 l/min after administration of 1.5 mg/kg MDMA (Lester et al., 2000). MDMA induced a 
significant rise in body temperature of about 0.2-0.8° C (Liechti, 2014). Further acute 
sympathomimetic effects include pupil dilation, trismus and bruxism, nystagmus, loss of appetite, 
and in males, possible erectile dysfunction (Downing, 1986; Hysek and Liechti, 2012). 
Taken together, responses to MDMA are both stimulating with amphetamine-like 
sympathomimetic effects, and “entactogen” with oxytocin-like sociable effects (Figure 1 – 2). 
 
  
Figure 1 Subjective effects of MDMA (125 mg), methylphenidate (60 mg), modafinil (600mg), and placebo on the 
visual analog scales (VASs). MDMA produced greater subjective effect ratings for any drug effects, good drug effects, 
drug liking, happiness, trust, and feeling close to others than methylphenidate, modafinil, and placebo. None of the 
substances produced significant bad drug effects compared with placebo. The data are expressed as the mean ± 
SEM in 24 subjects. The substance was administered at t = 0. (Dolder et al., 2018) 
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Figure 2 Autonomic responses to MDMA (125 mg), methylphenidate (60 mg), modafinil (600 mg), and placebo. 
MDMA showed higher increases in blood pressure than methylphenidate, modafinil, and placebo. The overall 
hemodynamic response, expressed as the rate-pressure product, similarly increased after all active treatments 
compared with placebo. The data are expressed as the mean ± SEM in 24 subjects. The substance was administered 
at t = 0. (Dolder et al., 2018)  
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1.3. Metabolism & Pharmacokinetics of MDMA 
PARAMETER CMAX TMAX AUC27H AUC∞ KE T1/2Β CLP CLH CLR 
UNIT µg/L hmedian µg×h/L µg×h/L 1/h h L/h L/h L/h 
MEAN VALUE 
± SD 
233 
± 45 
1.5 
2542 
± 469 
2866 
± 579 
0.086 
± 0.018 
8.3 
± 1.4 
36.3 
± 8.4 
26.9 
± 5.6 
9.4 
± 3.8 
Table 1 Pharmacokinetic parameters after a single oral dose of 100 mg MDMA in seven healthy male subjects (Segura 
et al., 2005). Cmax; maximum plasma concentration; Tmax, time to reach Cmax; AUC, area under the time-concentration 
curve; Ke, elimination rate constant; T1/2β, elimination half-life; CLp, plasmatic clearance; CLh, hepatic clearance; CLr, 
renal clearance. 
MDMA is usually taken orally and rapidly absorbed (de la Torre et al., 2000a). The major 
metabolic pathway is mainly regulated by cytochrome P450 (CYP) 2D6 and catechol-O-
methyltransferase (COMT; Figure 3), leading over an O-demethylenation to 3,4-
dihydroxymethamphetamine (HHMA). This step is predominantly mediated by CYP2D6 (Farre 
et al., 2004; Meyer et al., 2008). The O-demethylenation is regulated for about 30% by CYP2D6. 
MDMA is an uncompetitive mechanism-based inhibitor (MBI) of CYP2D6, resulting in an 
irreversible inhibition within 2 hours, and reaching phenotypical poor metabolizer activity (Farre 
et al., 2004; O'Mathuna et al., 2008). CYP2D6 activity recovers only after ten days with a recovery 
half-life of about 47 hours (O'Mathuna et al., 2008). The non-linearity of MDMA 
pharmacokinetics implies that relatively small increases in the dose of MDMA ingested are 
translated to disproportionate rises in MDMA plasma concentrations. Hence subjects with a 
higher dose might be more prone to develop acute toxicity (de la Torre et al., 2000a; de la Torre 
et al., 2000b). As shown in Figure 3, the minor pathway leads over N-demethylation regulated 
by CYP2B6, but also partly by CYP1A2 and to some extent by CYP2D6, to 3,4-
methylendioxyamphetamine (MDA) and through O-demethylenation to 3,4-
dihydroxyamphetamine (HHA; de la Torre et al., 2000b). HHMA and HHA is further O-
methylated by COMT to 4-hydroxy-3-methoxymethamphetamine (HMMA) and 4-hydroxy-3-
methoxyamphetamine (HMA), respectively, and conjugated by phase II enzymes in an O-
glucuronidation- or O-sulfation form before they are excreted in urine (Ensslin et al., 1996). 
Furthermore, approximately 15% of the administered MDMA dose is excreted unchanged in urine 
(Abraham et al., 2009). CYP2C19 was observed having a preference for the S-enantiomer. This 
enantioselective metabolism may be an explanation for the enantioselective pharmacokinetics of 
MDMA (Meyer et al., 2008). 
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Figure 3. Simplified hepatic metabolism pathways of racemic MDMA in human. Bold arrows mark the major 
metabolic pathway. Red circles show the detached/added part by metabolic action. CYP2C19 is not shown in this figure, 
because it is not equally important for both MDMA enantiomer. 
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1.4. Safety & Toxicology of MDMA 
“All things are poison, and nothing is without poison, the dosage alone makes it so a thing 
is not a poison.” This famous quote by Paracelsus seems to be only partially true for MDMA. At 
least, there is evidence of an idiosyncratic drug reaction in cases of severe liver damage (Henry et 
al., 1992; Ellis et al., 1996; Antolino-Lobo et al., 2011; Atayan et al., 2015; Maharaj et al., 2015). 
Cases of excessive regular use or 40-50 tablets of MDMA on one occasion did not end fatally, while 
on the other hand reported consumption of only one pill caused mortality (Henry et al., 1992; 
Parrott et al., 2001). It is, however, not reported how much active substance was present in those 
cases. In general, it is shown that the metabolites HHMA and HHA are more cytotoxic than the 
parent compound by forming reactive oxygen and nitrogen species (Kreth et al., 2000; Monks et 
al., 2004; Carmo et al., 2006; Antolino-Lobo et al., 2010). Furthermore, both MDMA and its 
active metabolite MDA are thought to be serotonergic neurotoxins, but did not manifest any 
neurotoxicity directly injected into the brain (Esteban et al., 2001). It is also postulated that minor 
systemic metabolites may be directly responsible for the neurotoxicity. Animal studies showed 
MDMA-related gradual loss of serotonergic axon terminals as well as cognitive functions 
(Ricaurte et al., 1985; de la Torre and Farre, 2004; Puerta et al., 2009). In human, neuroimaging 
studies found serotonergic deficits and memory impairments in heavy MDMA users (Gouzoulis-
Mayfrank and Daumann, 2006; Parrott, 2013). However, in some cases partial reconstitution may 
occur after abstinence or cognitive impairment may even never become an issue (Halpern et al., 
2004; Wagner et al., 2013).  
In general, the extent of toxicity of MDMA is difficult to determine. In most of the known 
MDMA-related emergencies, other substances like alcohol, cocaine, nicotine and many further 
play a more or less relevant role (Liechti et al., 2005; Antolino-Lobo et al., 2011; Roxburgh and 
Lappin, 2019). In fact, evidence-based analyses placed MDMA in a rather “safe” spot in relation 
to other illicit drugs (Nutt et al., 2007; Nutt et al., 2010). Nevertheless, among several MDMA 
adverse effects like tachyarrhythmia, loss of consciousness, depressive mood, dizziness or 
weakness and anxiety, hyperthermia and hyponatremia are considered to be the most life-
threatening acute physiological consequences of MDMA intoxications (Henry, 1992; Henry et al., 
1992; Kalant, 2001; Liechti et al., 2001a). While moderate elevated body temperatures (>38 °C) 
are to be expected in controlled settings, body temperatures over 42 °C have been reported in 
emergency cases (Green et al., 1995; Ellis et al., 1996; Liechti, 2014). It is suggested that MDMA 
stimulates the hypothalamic-pituitary-adrenal axis, the 5-HT, and the sympathetic system, and 
the hereby caused increases in cortisol, 5-HT, and NE levels contribute to the increase in body 
temperature (Liechti et al., 2000b; Hysek et al., 2011; Seibert et al., 2014). However, the 
mediation role of 5-HT in the thermogenic response to MDMA is somewhat unclear (Liechti et 
al., 2000b; Liechti and Vollenweider, 2000b; Farre et al., 2007), while the role of NE and α1- and 
β3-adrenergic receptors seems to be more conclusive (Sprague et al., 2003; Hysek et al., 2011; 
Hysek et al., 2012c; Hysek et al., 2013). Hyperthermia is followed by vasodilatation inducing 
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cutaneous blood flow and therefore enhancing the heat dissipation. The vasoconstriction effect of 
MDMA impairs this counteraction of the body (Pedersen and Blessing, 2001; Mills et al., 2004). 
In addition, the activation of the mitochondrial uncoupling protein 3 (UCP 3) induced by NE-
release could represent a further heat generation mechanism (Mills et al., 2004; Sprague et al., 
2004; Parrott, 2012). However, another factor is closely related to life threatening hyperthermia. 
MDMA is often consumed in crowded, hot environments such as raves (Schwartz and Miller, 
1997). High ambient temperatures, prolonged dancing, and dehydration take a significant 
account to the MDMA-induced hyperthermia (Patel et al., 2005; Capela et al., 2006; Parrott, 
2012). To counteract dehydration, women in particular should be careful and replace hypotonic 
water with an electrolyte-containing drink, as MDMA-induced hyponatremia is another 
potentially life-threatening condition that is fostered by excessive fluid intake (Rosenson et al., 
2007). MDMA-related hyponatremia is possibly caused by the inexpedient secretion of arginine 
vasopressin (AVP) by HMMA inducing water retention in combination with extreme physical 
activity and increased body temperature (Holden and Jackson, 1996; Henry et al., 1998; Cherney 
et al., 2002; Fallon et al., 2002; Hartung et al., 2002). This phenomenon is seen to be more 
frequently occurring in women (Rosenson et al., 2007; Bora et al., 2016).  
Substances that are widely used recreationally are often prone to lead to dependency. 
MDMA is popular in recreational settings like night clubs and “raves” (Schwartz and Miller, 1997), 
however, its dependence potential is questionable (Degenhardt et al., 2010). In a review in a 
cohort of over 6700 ecstasy users a minority was concerned about their use pattern (Degenhardt 
et al., 2010). MDMA seems to be a less potent reinforcer than other drugs, interestingly also 
significantly less than other popular stimulants (Degenhardt et al., 2010). The dependency profile 
of MDMA is arguably more similar to the hallucinogen class, which are hardly addictive, but not 
undisputed (Liechti and Vollenweider, 2000b; Cottler et al., 2009). An explanation for this matter 
might be that drug dependency is directly or indirectly tied to a dopaminergic pathway of action 
(Nestler, 2005). Despite dopaminergic activity, the effects of MDMA rely more on the 
norepinephrine and serotonergic mechanism of action (Hysek et al., 2012d; Simmler et al., 2013). 
Even though MDMA demonstrated self-administration behavior in rats, the 5-HT release was also 
found to attenuate the reinforcing effects compared with other amphetamines (Bankson and 
Yamamoto, 2004; Schenk et al., 2007).  
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1.5. Pharmacogenetics of MDMA 
As mentioned above, metabolism and transporter/receptor as mechanism of action seem 
to influence the effects of MDMA. Some of these players can be differently expressed due to 
different genetic disposition and therefore elicit interindividual differences in the response to 
MDMA exposure. The various genotypes are mostly caused by so-called single nucleotide 
polymorphisms (SNPs) but also gene deletions or duplications. The predominantly involved 
phase I enzyme for the metabolism of MDMA, CYP2D6, exhibits a high polymorphism in 
phenotypes with several different observed genotypes. Genetic poor metabolizers (PM) are 
observed in 5-10%, intermediate metabolizers (IM) in 10-17%, extensive metabolizers (EM) in 70-
80%, and ultra-rapid metabolizers in 3-5% of the Caucasian population (Sachse et al., 1997; Hicks 
et al., 2013; Preissner et al., 2013). CYP2D6 PMs were typically not represented in previous 
studies that evaluated the pharmacokinetics of MDMA. Hence, an MDMA pharmacokinetic study 
not including PMs found no effects of CYP2D6 genotype on plasma MDMA concentrations or its 
associated physiological response (Pardo-Lozano et al., 2012). In another study, a subject 
categorized as PM with a low enzyme activity displayed three times higher MDMA concentrations 
compared to normal activity EMs (de la Torre et al., 2005). In line with this, higher HMMA plasma 
levels were observed in subjects with two functional alleles of CYP2D6 (Pardo-Lozano et al., 
2012). However, it was postulated that the autoinhibitory behavior of MDMA on CYP2D6 implies 
that subjects, irrespective of their genotype, are phenocopied into PMs. It is even suggested that 
the PM genotype of CYP2D6 prevents long-term neurotoxicity, since the toxicity was linked to 
minor metabolites of MDMA after its methylenedioxyphenyl ring-opening by CYP2D6 (de la 
Torre and Farre, 2004; Carmo et al., 2006). The phase II enzyme COMT shows a well-studied 
SNP that results in an amino acid exchange from valine (Val) to methionine (Met) in position 158 
of the amino acid sequence (Green et al., 2003). The Val-allele is associated with a high, and the 
Met-allele with a low activity of the COMT enzyme. An association has been observed between 
low COMT activity and a higher increase in plasma cortisol concentration and lower plasma 
sodium compared to high COMT activity after MDMA administration (Aitchison et al., 2012; 
Wolff et al., 2012). Surprisingly, a study in 27 healthy subjects has shown greater cardiovascular 
effects and lower negative subjective effects such as dizziness, sedation, and anxiety in carriers 
with the high functionality COMT genotype after MDMA administration (Pardo-Lozano et al., 
2012). The same study found also greater cardiovascular effects in long allele carriers of the 5-HT-
transporter-linked polymorphic region (5-HTTLPR) compared to exclusive short allele carriers 
(Pardo-Lozano et al., 2012). Other pharmacodynamic targets of MDMA were not investigated yet, 
except an oxytocin receptor gene (OXTR) polymorphism defined by the SNP rs53576. Bershad et 
al. found that sociability did not increase in individuals carrying the rs53576 AA genotype vs 
individuals with at least one G allele after a high dose (1.5 mg/kg) of MDMA (Bershad et al., 
2016b). In addition, recent research has started to determine potential genetic differences that 
may underlie the individual response to d-amphetamine (Dlugos et al., 2007; Hamidovic et al., 
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2010a; b; Dlugos et al., 2011). For example, it has been shown that polymorphisms in the DA 
transporter (Solute Carrier 6A3, SLC6A3) were associated with stimulant effects of amphetamine. 
Specifically, individuals with the C/C genotype at rs460000 reported twofold higher stimulation 
and euphoria relative to the A/A or A/C genotype group (Hamidovic et al., 2010b). Different 
studies from the same group reported many positive associations between SNPs and subjective 
effects of d-amphetamine although these could not all be replicated in a larger study sample (Hart 
et al., 2013). While many gene polymorphism-drug effect associations were clearly not confirmed, 
some interesting ones for MDMA were reconfirmed including DAT (3’UTRVNTR, rs460000) and 
trends for NET rs1861647 (Hart et al., 2013).  
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1.6. Significance 
In Switzerland, 3.9% of the population reported having used Ecstasy at least once in their 
life (Gmel G., 2017). MDMA is the active substance usually found in Ecstasy pills. But MDMA is 
not only recreationally used, it is also being evaluated as a treatment for post-traumatic stress 
disorder in several countries including Switzerland (Oehen et al., 2013; Mithoefer et al., 2016; 
Mithoefer et al., 2018). MDMA has also been suggested to be useful to treat and study mood 
disorders due to its potential to increase empathy and rapidly elevate mood (Brensilver et al., 
2012). So far, MDMA was tested in several studies with healthy subjects and patients. However, 
the safety pharmacology and pharmacogenetics of MDMA is poorly characterized and needs to be 
tested within a reasonable sample size. Linking genetics to MDMA effect variability helps to 
elucidate individual drug responses and toxicity. Unfortunately, such linking studies are scarce or 
absent for many polymorphisms on a pharmacokinetic and -dynamic level. Previous 
pharmacogenetic studies with MDMA did not reach a sufficient sample size to come to a revealing 
conclusion. More research is necessary to unravel which polymorphisms are of clinical relevance. 
This thesis shows several new analyses within the largest pooled but consistent study cohort of 
healthy subjects tested with MDMA.  
 
1.7. Aims & Hypothesis 
The main goal of this thesis was to add completive information to the safety 
pharmacological and pharmacogenetics of MDMA, a substance that is widely used recreationally 
and likely to be used soon as a medication for the treatment of PTSD. 
The first aim was to point out the frequency and magnitude of adverse events of one or two 
single-dose administrations of MDMA at doses similar or equal to the ones used in MDMA-
assisted therapy. We hypothesized that MDMA would produce predominantly acute positive 
mood effects and tolerable transient cardiostimulant and thermogenic reactions. Changes in liver 
enzymes or creatine levels as a sign of liver damage or renal failure were not expected in a 
controlled setting. 
Our hypotheses for the different pharmacogenetic studies were diverse and depended on 
the target and a few preliminary findings from earlier studies of effects of different genetic 
polymorphisms on the effects of stimulants. In general, we only investigated the influence of 
genetic polymorphisms that were prominent in the Caucasian population (>1%) and that were 
thought to be functional. 
We hypothesized that the pharmacokinetics would be influenced according to the 
genetically determined activity levels of the CYPs and the involved MDMA metabolism pathways. 
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Specifically, we expected that CYP2D6 poor metabolizers would show higher concentrations of 
MDMA than normal metabolizers, and tobacco smokers with the inducible variant of CYP1A2 
would likely show a higher formation of MDA compared to non-smokers and smokers with the 
non-inducible variant of CYP1A2. If the genetic polymorphisms of the MDMA-metabolizing CYPs 
would also alter pharmacodynamic parameters was an additional aim of this study. 
Many data are available on interactions between monoamine transporter (NET, SERT, 
DAT) inhibitors and MDMA. These observations together with rare existing pharmacogenetic 
data on the effects of genetic polymorphism on stimulant drugs and / or MDMA led to our 
hypotheses for polymorphisms in genes coding for the respective monoamine system. Two 
smaller previous studies highlighted modification of the cardiovascular effects and the anxiety felt 
after MDMA administration caused by 5-HTTLPR polymorphisms (see 1.5 Pharmacogenetics). 
We expected to replicate those previous results. Variations within genes coding for the serotonin 
system were additionally tested for alterations to the acute responses to MDMA, since the 
serotonin system is thought to play a major role in the mediation of most MDMA effects. For the 
impact of genotypes within the NE and DA system on the effects of MDMA, no preliminary results 
were existing. However, since NE was shown to be critically involved in the mediation of the 
cardio- and psychostimulant effects of MDMA, we suspected a modification in the MDMA-
induced increase of subjective stimulant effects and the rate-pressure product. The interaction of 
MDMA with the DA system is suspected be vague responsible for the acute effects of MDMA. 
Because of previous interaction studies and low affinity to the DAT, we hypothesized none to 
minimal influence of variants within genes coding for the DA system on the acute effects of 
MDMA.  
Because oxytocin is known to influence prosociality, the hypothesis for the OXTR 
polymorphism was that we would observe changes in the prosocial effects of MDMA and replicate 
previous findings regarding the role of an OXTR SNP and the prosocial response to MDMA. 
Therefore, we focused on visual analog scales (VAS) like “trust” and “closeness to others” as well 
as several tests to assess altruism, and emotional and cognitive empathy. 
Due to the explanatory nature of the pharmacogenetic studies in this thesis, we accounted 
for multiple comparisons in the statistical results.  
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The scope of present thesis describes comprehensive safety pharmacology and 
pharmacogenetics of MDMA in healthy human subjects. The study findings are detailed in the 
published papers above. Here is a brief discussion of the whole work, a conclusion and an outlook. 
Safety pharmacology of MDMA 
MDMA effected predominantly acute positive subjective sensations. The administration of 
MDMA at doses of 75 and 125 mg was overall safe and well tolerated in healthy subjects. 
Unpleasant subjective drug effects and adverse effects were more pronounced in women. Lack of 
appetite, dry mouth, cold feet, sweating, restlessness and palpitations were the most frequent 
acute adverse events reported, indicating moderate sympathomimetic toxicity. Transient 
hypertension (systolic blood pressure >160 mmHg) and tachycardia (heart rate >100 beats/min) 
were observed in one third of the participants who received 125 mg MDMA. 5 % of the subjects 
reached transient systolic blood pressure peaks over 180 mmHg, which is considered as severe 
hypertension. However, no clinical symptoms of hypertensive crises were observed and the results 
were comparable with cardiovascular stimulation in other studies with MDMA or other 
stimulants such as D-amphetamine, methylphenidate, and methamphetamine (Kirkpatrick et al., 
2012; Wardle et al., 2012; Hysek et al., 2014b; Bershad et al., 2015). Special attention was paid to 
the thermogenic reaction to MDMA, since hyperpyrexia is considered as the most important life-
threatening complication of MDMA use (Liechti et al., 2005; Halpern et al., 2011; Liechti, 2014). 
Body temperature increased up to 39.1 °C in our studies, which is consistent with other controlled 
trials (Freedman et al., 2005; Kolbrich et al., 2008). However, the results should be cautiously 
compared to emergencies, since there are often additional risk factors such as high ambient 
temperature in recreational settings (Dafters, 1995). Levels of liver enzymes and kidney function 
did not differ before and one month after MDMA administration. Although we did not 
hypothesize hepatotoxic effects at the doses used, idiosyncratic hepatotoxicity is reported in rare 
cases (Henry et al., 1992; Ellis et al., 1996; Antolino-Lobo et al., 2011; Atayan et al., 2015; Maharaj 
et al., 2015). This type of hepatotoxicity is observed with many marketed medications 
(Krähenbühl and J.Pichler, 2017).  
Due to the aforementioned results, administration of a fix dose of 100 mg MDMA for women 
and 125 mg dose for men is suggested. In line with our recommendation, phase 3 trials use 80 mg 
of MDMA with the option to escalate the dose up to 120 mg (Mithoefer et al., 2019). Our data did 
not raise any safety concerns related to further studies of MDMA in controlled medical 
environments, including as an adjunct to psychotherapy. However, these results should be 
interpreted with caution, as only healthy subjects were included, and sympathomimetic 
stimulation has been observed. To assess this matter, further research should be conducted with 
patients suffering from (somatic) comorbidities, and those at risk for sympathomimetic toxicity.  
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Pharmacogenetic profiles of MDMA 
MDMA is a stimulant and an entactogen (Nichols, 1986; Bershad et al., 2016a). Subjects 
taking MDMA display distinct subjective, prosocial, and autonomic effects (Hysek et al., 2014a; 
Schmid et al., 2014). However, there is individual variation in the effects of MDMA. Some of this 
variance may be explained by different genetic predispositions of the pharmacokinetic and 
pharmacodynamic players involved in the response to MDMA in humans. 
For example, CYP2D6 plays a major role in the metabolism of MDMA (de la Torre et al., 
2012; Rietjens et al., 2012; Yubero-Lahoz et al., 2012). We confirmed in a meaningful sample size 
the critical involvement of CYP2D6 genotypes and underlined the results with phenotype data. In 
addition, we showed for the first time the influence of polymorphism in CYP1A2, CYP2B6, and 
CYP2C19 on the pharmacokinetic and pharmacodynamic response to MDMA in humans. Results 
display that subjects with CYP2D6 poor metabolizer status had a disabled major metabolic 
pathway and therefore exhibited higher MDMA and MDA, and lower HMMA blood plasma 
concentrations compared with subjects identified as extensive metabolizer (normal). CYP2D6 
PMs also showed a more rapid increase of the subjective and autonomic drug effects in the 
beginning of the acute MDMA effects. These findings are consistent with the previously observed 
mechanism-based inhibition of CYP2D6 that turns all subjects into functional PMs within 1-2 h 
(Yang et al., 2006; O'Mathuna et al., 2008). When CYP2D6 function decreases over time, other 
CYPs might become more important. We showed, consistent with in vitro studies (Kreth et al., 
2000; Meyer et al., 2008), that CYP2B6, CYP1A2, and CYP2C19 contributed to the conversion of 
MDMA to MDA in humans. In line with the auto-inhibition of CYP2D6, the influence of 
polymorphisms in the CYP2B6 became more apparent 3-4 h after MDMA administration. 
Furthermore, we found higher MDA levels in subjects who smoke 6-10 cigarettes a day and 
possess the inducible genotype of the CYP1A2 compared with subjects who smoke less and/or 
have the non-inducible polymorphism. However, we tested only very moderate smokers and only 
4 had the inducible type. If this result remains significant in study cohorts with more and heavier 
smokers is still to investigate. So far, the consequences of this enhanced conversion from MDMA 
to MDA are unclear. Since the effect and toxicity of MDA is similar to MDMA, this may not be 
clinically relevant (Molliver et al., 1986; Esteban et al., 2001; Monks et al., 2004; Baggott et al., 
2019).  
In a second part of this thesis, we focused on the pharmacodynamic effect of MDMA and 
looked into pharmacological targets of the MDMA mechanism. MDMA acts primarily through the 
release and reuptake inhibition of 5-HT, NE, and DA, but also increases oxytocin levels 
(Thompson et al., 2007; Dumont et al., 2009; Hysek et al., 2012d; Simmler et al., 2013; Hysek et 
al., 2014a; Kirkpatrick et al., 2014). Polymorphisms in genes coding for components of those 
monoamine and neuroendocrine systems were investigated for their influence on the response to 
MDMA. Regarding the polymorphisms in the OXTR (3 SNPs) we suspected alterations in the 
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prosocial effects, since a clinical study indicated different sociability after MDMA (Bershad et al., 
2016b). Additionally, oxytocin is known to increase similar empathogenic effects (Di Simplicio et 
al., 2009; Hurlemann et al., 2010). In fact, we observed moderating effects for MDMA-induced 
feelings of trust and desire for company, but between genotype groups of another SNP 
(rs1042778) than was indicated by the previous study (rs53576).  
As for the investigations on the monoamine system genes and their influence on MDMA 
effects, this thesis was the first research conducted for most of the tested polymorphisms. 
Therefore, results had to be carefully corrected for statistical errors and tested predominantly for 
plausible effects (e.g. NET gene [SLC6A2] for cardiovascular effects). Most of the tested genetic 
polymorphisms in the 5-HT (7 SNPs and 1 repeat polymorphism), NE (5 SNPs), and DA (10 SNPs 
and 1 repeat polymorphism) systems did not alter the effects of MDMA when adjusting for 
multiple comparisons. Despite rigorous correction to avoid Type I errors, some polymorphisms 
in the NE gene SLC6A2 (rs1861647, rs2242446, rs36029) slightly, but significantly, moderated 
the acute MDMA-induced cardiovascular response. Furthermore, variations in genes that encode 
key targets in the 5-HT system (rs7305115, rs6313, 5-HTTLPR) tended to moderate some MDMA 
effects such as “good drug effect”, “drug liking”, or “closeness to others”. Before correction for 
multiple testing the results from the present study reproduced the non-corrected results from a 
recent study by Kuypers et al. (Kuypers et al., 2018). In both studies, carriers of the short allele 
(5-HTTLPR) felt less MDMA-induced anxiety/fear than carriers of two long alleles. However, an 
influence by 5-HT system gene variations on cardiovascular effects of MDMA were not observed. 
Subsequently, this thesis is failing to replicate findings from another study showing greater 
cardiovascular effects in long allele carriers of the 5-HTTLPR compared to exclusive short allele 
carriers (Pardo-Lozano et al., 2012). Nevertheless, the present thesis was conducted with a higher 
sample size and a more methodologically sound analysis. Furthermore, results from 
pharmacogenetic studies with d-amphetamine and polymorphisms within SLC6A2 and SLC6A3 
could also not be replicated for MDMA (Dlugos et al., 2007; Dlugos et al., 2011), but were also 
contradicted by the same group in a follow-up study (Hart et al., 2013). Altogether, genetic 
polymorphisms in the monoamine systems may play a marginal role in acute MDMA effects and 
are unlikely to explain the whole spectrum of interindividual variations. 
Limitations & Outlook 
While the data provide valuable insight into safety pharmacology and the 
pharmacogenetics of MDMA in humans, some limitations should be kept in mind.  
First of all, we examined only healthy and mostly young volunteers. Translating results 
from phase I studies to psychiatric patients or people with special health conditions and probable 
co-medication is limited and needs further investigation. A second limitation but also strength of 
this cohort is its uniformity. Our participants are predominantly of European descent. Thus, the 
relevance and reproducibility of the results may vary between ethnicity. For example, CYP2D6 
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genotype frequencies differ considerably across the major ethnic groups (Gaedigk et al., 2017). 
Furthermore, although this is the largest standardized MDMA cohort to date, some rare 
mutations and especially rare haplotypes might be missed. 
Another clear limitation is that additional players involved in MDMA effects feature 
genetic variations as well. For instance, COMT gene contains a main functional SNP (rs4680) that 
results in an amino acid exchange from Val to Met. The COMT Val-allele is associated with a high, 
and the Met-allele with a low activity of the enzyme (Maria et al., 2012). As mentioned before (see 
section 1.3.), COMT is an important enzyme in the metabolism of MDMA. Therefore, the COMT 
polymorphism might have an impact on the acute effects of MDMA. In fact, a study has shown 
influence on the cardiovascular effects, while others associated low COMT activity with a higher 
increase in plasma cortisol concentration and lower plasma sodium after MDMA administration 
(Aitchison et al., 2012; Pardo-Lozano et al., 2012; Wolff et al., 2012). Another target worth 
investigating might be the monoamino oxidase A (MOA-A). It catalyzes oxidative deamination of 
several monoamines including www5-HT, NE, and DA. Steuer et al. showed relevant inhibition 
(>30%) of MDA and MDMA toward MAO-A catalyzed deamination of DA and 5-HT (Steuer et al., 
2016). There is a known variable number tandem repeat (VNTR) promoter polymorphism and an 
SNP (rs6323) that modifies the MAO-A expression (Sabol et al., 1998; Verma et al., 2014). Further 
studies should examine the impact of those polymorphism on clinical pharmacology of MDMA. 
Moreover, individual differences in the UCP3 gene may modulate the hyperthermic effects of 
MDMA since UCP3 is involved in thermogenesis through uncoupling of mitochondrial oxidative 
phosphorylation in skeletal muscle (Brand and Esteves, 2005). Interestingly, in knock-out mice 
deficient in UCP3 the thermogenic response to MDMA was diminished (Mills et al., 2003). The 
hyperthermic reaction to MDMA is one of the most dangerous effects, and genetic factors that 
might be involved should be discussed separately in the scope of a future publication. Also worth 
mentioning are mutations in genes coding for the trace amine-associated receptor (TAAR1) or the 
arginine vasopressin receptor 1A (AVPR1A) that could alter some effects of MDMA. TAAR1 is 
involved in the triggering of the phosphorylation of DAT, NET, and SERT, which reverse the 
transport from the cytosol into the synaptic cleft (Miller, 2011; Simmler et al., 2016). AVPR1A 
gene variations could alter possibly the risk of hyponatremia and the prosocial effects of MDMA 
similarly to the findings of the OXTR genotypes (Knafo et al., 2008; Avinun et al., 2011). 
Certainly, there are several additional targets with genetic variations involved in MDMA 
effects that should be investigated in the future. However, not all mutations are in fact functional 
and pharmacogenetic studies are mostly designed retrospectively and thus observational. 
Prospective studies would be needed to confirm the here seen results. Additionally, to identify risk 
genetic polymorphisms for MDMA intoxications a database from a network like the European 
Drug Emergencies Network (Euro-DEN Plus) should be developed that also includes genetic 
information. However, linking genetics to MDMA response variability is not the only way to 
predict individual drug responses. An ongoing investigation in our study sample, displays 
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different predictors of the response to MDMA including character traits, mood before drug intake, 
and previous drug experience, as it has been showed for psilocybin (Studerus et al., 2012).  
In the coming years, phase 3 studies will likely reveal further details about the clinical 
safety of MDMA in a broader population. Results from the present studies may pave the way for 
future studies with MDMA in larger sample sizes and help to evaluate what is important for 
individually different responses to MDMA intake and just as much what is not.  
 
 
 130 
 
 
  
 131 
 
 
REFERENCE LIST 
 132 
 
  
Reference List 
 
133 
 
Abraham, T.T., Barnes, A.J., Lowe, R.H., Kolbrich Spargo, E.A., Milman, G., Pirnay, S.O., et al. 
(2009). Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA 
administration to humans. J Anal Toxicol 33(8), 439-446. 
Aitchison, K.J., Tsapakis, E.M., Huezo-Diaz, P., Kerwin, R.W., Forsling, M.L., and Wolff, K. 
(2012). Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in 
CYP2D6 and COMT. J Psychopharmacol 26(3), 408-418. 
Antolino-Lobo, I., Meulenbelt, J., Nijmeijer, S.M., Scherpenisse, P., van den Berg, M., and van 
Duursen, M.B. (2010). Differential roles of phase I and phase II enzymes in 3,4-
methylendioxymethamphetamine-induced cytotoxicity. Drug Metab Dispos 38(7), 1105-
1112. 
Antolino-Lobo, I., Meulenbelt, J., van den Berg, M., and van Duursen, M.B. (2011). A mechanistic 
insight into 3,4-methylenedioxymethamphetamine ("ecstasy")-mediated hepatotoxicity. 
Vet Q 31(4), 193-205. 
Atayan, Y., Cagin, Y.F., Erdogan, M.A., Harputluoglu, M.M., and Bilgic, Y. (2015). Ecstasy induced 
acute hepatic failure. Case reports. Acta Gastroenterol Belg 78(1), 53-55. 
Avinun, R., Israel, S., Shalev, I., Gritsenko, I., Bornstein, G., Ebstein, R.P., et al. (2011). AVPR1A 
variant associated with preschoolers' lower altruistic behavior. PLoS One 6(9), e25274. 
Baggott, M.J., Garrison, K.J., Coyle, J.R., Galloway, G.P., Barnes, A.J., Huestis, M.A., et al. (2019). 
Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in 
Healthy Volunteers. J Psychoactive Drugs 51(2), 108-117. 
Bankson, M.G., and Yamamoto, B.K. (2004). Serotonin-GABA interactions modulate MDMA-
induced mesolimbic dopamine release. J Neurochem 91(4), 852-859. 
Battaglia, G., Brooks, B.P., Kulsakdinun, C., and De Souza, E.B. (1988). Pharmacologic profile of 
MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J 
Pharmacol 149(1-2), 159-163. 
Bedi, G., Phan, K.L., Angstadt, M., and de Wit, H. (2009). Effects of MDMA on sociability and 
neural response to social threat and social reward. Psychopharmacology (Berl) 207(1), 
73-83. 
Benzenhofer, U., and Passie, T. (2006). The early history of "ecstasy". Nervenarzt, 77(1), 95-6, 
98-9. 
Berger, U.V., Gu, X.F., and Azmitia, E.C. (1992). The substituted amphetamines 3,4-
methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and 
fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by 
fluoxetine and cocaine. Eur J Pharmacol 215(2-3), 153-160. 
Bershad, A.K., Kirkpatrick, M.G., Seiden, J.A., and de Wit, H. (2015). Effects of acute doses of 
prosocial drugs methamphetamine and alcohol on plasma oxytocin levels. J Clin 
Psychopharmacol 35(3), 308-312. 
Reference List 
 
134 
 
Bershad, A.K., Miller, M.A., Baggott, M.J., and de Wit, H. (2016a). The effects of MDMA on socio-
emotional processing: does MDMA differ from other stimulants? J Psychopharmacol 30, 
1248-1258. 
Bershad, A.K., Weafer, J.J., Kirkpatrick, M.G., Wardle, M.C., Miller, M.A., and de Wit, H. (2016b). 
Oxytocin receptor gene variation predicts subjective responses to MDMA. Soc Neurosci 
11(6), 592-599. 
Bora, F., Yilmaz, F., and Bora, T. (2016). Ecstasy (MDMA) and its effects on kidneys and their 
treatment: a review. Iran J Basic Med Sci 19(11), 1151-1158. 
Brand, M.D., and Esteves, T.C. (2005). Physiological functions of the mitochondrial uncoupling 
proteins UCP2 and UCP3. Cell Metab 2(2), 85-93. 
Brensilver, M., Heinzerling, K.G., Swanson, A.N., and Shoptaw, S.J. (2012). A retrospective 
analysis of two randomized trials of bupropion for methamphetamine dependence: 
Suggested guidelines for treatment discontinuation/augmentation. Drug Alcohol Depend 
125(1-2), 169-72. 
Capela, J.P., Meisel, A., Abreu, A.R., Branco, P.S., Ferreira, L.M., Lobo, A.M., et al. (2006). 
Neurotoxicity of Ecstasy metabolites in rat cortical neurons, and influence of 
hyperthermia. J Pharmacol Exp Ther 316(1), 53-61. 
Carmo, H., Brulport, M., Hermes, M., Oesch, F., Silva, R., Ferreira, L.M., et al. (2006). Influence 
of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('Ecstasy') 
cytotoxicity. Pharmacogenet Genomics 16(11), 789-799. 
Cherney, D.Z., Davids, M.R., and Halperin, M.L. (2002). Acute hyponatraemia and 'ecstasy': 
insights from a quantitative and integrative analysis. QJM 95(7), 475-483. 
Cottler, L.B., Leung, K.S., and Abdallah, A.B. (2009). Test-re-test reliability of DSM-IV adopted 
criteria for 3,4-methylenedioxymethamphetamine (MDMA) abuse and dependence: a 
cross-national study. Addiction 104(10), 1679-1690. 
Dafters, R.I. (1995). Hyperthermia following MDMA administration in rats: effects of ambient 
temperature, water consumption, and chronic dosing. Physiol Behav 58(5), 877-882. 
de la Torre, R., and Farre, M. (2004). Neurotoxicity of MDMA (ecstasy): the limitations of scaling 
from animals to humans. Trends Pharmacol Sci 25(10), 505-508. 
de la Torre, R., Farre, M., Mathuna, B.O., Roset, P.N., Pizarro, N., Segura, M., et al. (2005). 
MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 
extensive metabolisers. Eur J Clin Pharmacol 61(7), 551-554. 
de la Torre, R., Farre, M., Ortuno, J., Mas, M., Brenneisen, R., Roset, P.N., et al. (2000a). Non-
linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49(2), 104-
109. 
de la Torre, R., Farre, M., Roset, P.N., Lopez, C.H., Mas, M., Ortuno, J., et al. (2000b). 
Pharmacology of MDMA in humans. Ann N Y Acad Sci 914, 225-237. 
Reference List 
 
135 
 
de la Torre, R., Yubero-Lahoz, S., Pardo-Lozano, R., and Farre, M. (2012). MDMA, 
methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relvant? Front 
Genet 3, 235. 
Degenhardt, L., Bruno, R., and Topp, L. (2010). Is ecstasy a drug of dependence? Drug Alcohol 
Depend 107(1), 1-10. 
Di Simplicio, M., Massey-Chase, R., Cowen, P.J., and Harmer, C.J. (2009). Oxytocin enhances 
processing of positive versus negative emotional information in healthy male volunteers. 
J Psychopharmacol 23(3), 241-248. 
Dlugos, A., Freitag, C., Hohoff, C., McDonald, J., Cook, E.H., Deckert, J., et al. (2007). 
Norepinephrine transporter gene variation modulates acute response to D-amphetamine. 
Biol Psychiatry 61(11), 1296-1305. 
Dlugos, A.M., Hamidovic, A., Hodgkinson, C., Shen, P.H., Goldman, D., Palmer, A.A., et al. (2011). 
OPRM1 gene variants modulate amphetamine-induced euphoria in humans. Genes Brain 
Behav 10(2), 199-209. 
Doblin, R. (2002). A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress 
disorder (PTSD): partnering with the FDA. J Psychoactive Drugs 34(2), 185-194. 
Dolder, P.C., Muller, F., Schmid, Y., Borgwardt, S.J., and Liechti, M.E. (2018). Direct comparison 
of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, 
methylphenidate, and modafinil in healthy subjects. Psychopharmacology (Berl) 235(2), 
467-479. 
Downing, J. (1986). The psychological and physiological effects of MDMA on normal volunteers. 
J Psychoactive Drugs 18(4), 335-340. 
Dumont, G.J., Sweep, F.C., van der Steen, R., Hermsen, R., Donders, A.R., Touw, D.J., et al. 
(2009). Increased oxytocin concentrations and prosocial feelings in humans after ecstasy 
(3,4-methylenedioxymethamphetamine) administration. Soc Neurosci 4(4), 359-366. 
Ellis, A.J., Wendon, J.A., Portmann, B., and Williams, R. (1996). Acute liver damage and ecstasy 
ingestion. Gut 38(3), 454-458. 
Ensslin, H.K., Maurer, H.H., Gouzoulis, E., Hermle, L., and Kovar, K.A. (1996). Metabolism of 
racemic 3,4-methylenedioxyethylamphetamine in humans. Isolation, identification, 
quantification, and synthesis of urinary metabolites. Drug Metab Dispos 24(8), 813-820. 
Esteban, B., O'Shea, E., Camarero, J., Sanchez, V., Green, A.R., and Colado, M.I. (2001). 3,4-
Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when 
administered centrally at a concentration occurring following a peripherally injected 
neurotoxic dose. Psychopharmacology (Berl) 154(3), 251-260. 
Fallon, J.K., Shah, D., Kicman, A.T., Hutt, A.J., Henry, J.A., Cowan, D.A., et al. (2002). Action of 
MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann N Y Acad Sci 
965, 399-409. 
Farre, M., Abanades, S., Roset, P.N., Peiro, A.M., Torrens, M., O'Mathuna, B., et al. (2007). 
Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) 
Reference List 
 
136 
 
and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 
323(3), 954-962. 
Farre, M., de la Torre, R., Mathuna, B.O., Roset, P.N., Peiro, A.M., Torrens, M., et al. (2004). 
Repeated doses administration of MDMA in humans: pharmacological effects and 
pharmacokinetics. Psychopharmacology (Berl) 173(3-4), 364-375. 
Francis, S.M., Kirkpatrick, M.G., de Wit, H., and Jacob, S. (2016). Urinary and plasma oxytocin 
changes in response to MDMA or intranasal oxytocin administration. 
Psychoneuroendocrinology 74, 92-100. 
Freedman, R.R., Johanson, C.E., and Tancer, M.E. (2005). Thermoregulatory effects of 3,4-
methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 
183(2), 248-256. 
Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T., and Leeder, J.S. (2017). Prediction of 
CYP2D6 phenotype from genotype across world populations. Genet Med 19(1), 69-76. 
Gmel G., K.H., Notari L., Gmel C. (2017). Suchtmonitoring Schweiz - Konsum von Alkohol, Tabak 
und illegalen Drogen in der Schweiz im Jahr 2016. . Suchtmonitoring Schweiz, Sucht 
Schweiz. 
Gouzoulis-Mayfrank, E., and Daumann, J. (2006). The confounding problem of polydrug use in 
recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol 20(2), 188-193. 
Green, A.R., Cross, A.J., and Goodwin, G.M. (1995). Review of the pharmacology and clinical 
pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). 
Psychopharmacology 119(3), 247-260. 
Green, A.R., Mechan, A.O., Elliott, J.M., O'Shea, E., and Colado, M.I. (2003). The pharmacology 
and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). 
Pharmacol Rev 55(3), 463-508. 
Greer, G., and Strassman, R.J. (1985). Information on "Ecstasy". Am J Psychiatry 142(11), 1391. 
Grinspoon, L., and Bakalar, J.B. (1986). Can drugs be used to enhance the psychotherapeutic 
process? Am J Psychother 40(3), 393-404. 
Halpern, J.H., Pope, H.G., Jr., Sherwood, A.R., Barry, S., Hudson, J.I., and Yurgelun-Todd, D. 
(2004). Residual neuropsychological effects of illicit 3,4-
methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to 
other drugs. Drug Alcohol Depend 75(2), 135-147. 
Halpern, P., Moskovich, J., Avrahami, B., Bentur, Y., Soffer, D., and Peleg, K. (2011). Morbidity 
associated with MDMA (ecstasy) abuse: a survey of emergency department admissions. 
Hum Exp Toxicol 30(4), 259-266. 
Hamidovic, A., Dlugos, A., Palmer, A.A., and de Wit, H. (2010a). Catechol-O-methyltransferase 
val158met genotype modulates sustained attention in both the drug-free state and in 
response to amphetamine. Psychiatr Genet 20(3), 85-92. 
Hamidovic, A., Dlugos, A., Palmer, A.A., and de Wit, H. (2010b). Polymorphisms in dopamine 
transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an 
Reference List 
 
137 
 
exploratory pharmacogenetic study using healthy volunteers. Behav Genet 40(2), 255-
261. 
Hart, A.B., de Wit, H., and Palmer, A.A. (2013). Candidate gene studies of a promising 
intermediate phenotype: failure to replicate. Neuropsychopharmacology 38(5), 802-816. 
Hartung, T.K., Schofield, E., Short, A.I., Parr, M.J., and Henry, J.A. (2002). Hyponatraemic states 
following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. QJM 
95(7), 431-437. 
Henry, J.A. (1992). Ecstasy and the dance of death. BMJ 305(6844), 5-6. 
Henry, J.A., Fallon, J.K., Kicman, A.T., Hutt, A.J., Cowan, D.A., and Forsling, M. (1998). Low-
dose MDMA ("ecstasy") induces vasopressin secretion. Lancet 351(9118), 1784. 
Henry, J.A., Jeffreys, K.J., and Dawling, S. (1992). Toxicity and deaths from 3,4-
methylenedioxymethamphetamine ("ecstasy"). Lancet 340(8816), 384-387. 
Hicks, J.K., Swen, J.J., Thorn, C.F., Sangkuhl, K., Kharasch, E.D., Ellingrod, V.L., et al. (2013). 
Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and 
CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93(5), 
402-408. 
Holden, R., and Jackson, M.A. (1996). Near-fatal hyponatraemic coma due to vasopressin over-
secretion after "ecstasy" (3,4-MDMA). Lancet 347(9007), 1052. 
Hurlemann, R., Patin, A., Onur, O.A., Cohen, M.X., Baumgartner, T., Metzler, S., et al. (2010). 
Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional 
empathy in humans. J Neurosci 30(14), 4999-5007. 
Hysek, C.M., Brugger, R., Simmler, L.D., Bruggisser, M., Donzelli, M., Grouzmann, E., et al. 
(2012a). Effects of the alpha2-adrenergic agonist clonidine on the pharmacodynamics and 
pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J 
Pharmacol Exp Ther 340, 286-294. 
Hysek, C.M., Domes, G., and Liechti, M.E. (2012b). MDMA enhances "mind reading" of positive 
emotions and impairs "mind reading" of negative emotions. Psychopharmacology (Berl) 
222, 293-302. 
Hysek, C.M., Fink, A.E., Simmler, L.D., Donzelli, M., Grouzmann, E., and Liechti, M.E. (2013). 
Alpha-adrenergic receptors contribute to the acute effects of MDMA in humans. J Clin 
Psychopharmacol 33, 658-666. 
Hysek, C.M., and Liechti, M.E. (2012). Effects of MDMA alone and after pretreatement with 
reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. 
Psychopharmacology (Berl) 224, 363-376. 
Hysek, C.M., Schmid, Y., Rickli, A., Simmler, L.D., Donzelli, M., Grouzmann, E., et al. (2012c). 
Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br 
J Pharmacol 166, 2277-2288. 
Reference List 
 
138 
 
Hysek, C.M., Schmid, Y., Simmler, L.D., Domes, G., Heinrichs, M., Eisenegger, C., et al. (2014a). 
MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci 9, 
1645-1652. 
Hysek, C.M., Simmler, L.D., Ineichen, M., Grouzmann, E., Hoener, M.C., Brenneisen, R., et al. 
(2011). The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of 
MDMA ("ecstasy") in humans. Clin Pharmacol Ther 90(2), 246-255. 
Hysek, C.M., Simmler, L.D., Nicola, V., Vischer, N., Donzelli, M., Krähenbühl, S., et al. (2012d). 
Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized 
placebo-controlled laboratory study. PLoS One 7, e36476. 
Hysek, C.M., Simmler, L.D., Schillinger, N., Meyer, N., Schmid, Y., Donzelli, M., et al. (2014b). 
Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA 
administered alone and in combination. Int J Neuropsychopharmacol 17, 371-381. 
Kalant, H. (2001). The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. 
CMAJ 165(7), 917-928. 
Kirkpatrick, M.G., Gunderson, E.W., Perez, A.Y., Haney, M., Foltin, R.W., and Hart, C.L. (2012). 
A direct comparison of the behavioral and physiological effects of methamphetamine and 
3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 
219(1), 109-122. 
Kirkpatrick, M.G., Lee, R., Wardle, M.C., Jacob, S., and de Wit, H. (2014). Effects of MDMA and 
intranasal oxytocin on social and emotional processing. Neuropsychopharmacology 39, 
1654-1663. 
Knafo, A., Israel, S., Darvasi, A., Bachner-Melman, R., Uzefovsky, F., Cohen, L., et al. (2008). 
Individual differences in allocation of funds in the dictator game associated with length of 
the arginine vasopressin 1a receptor RS3 promoter region and correlation between RS3 
length and hippocampal mRNA. Genes Brain Behav 7(3), 266-275. 
Kolbrich, E.A., Goodwin, R.S., Gorelick, D.A., Hayes, R.J., Stein, E.A., and Huestis, M.A. (2008). 
Physiological and subjective responses to controlled oral 3,4-
methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28(4), 432-
440. 
Krähenbühl, S., and J.Pichler, W. (2017). Medikamentöse Hepatopathien. Therapeutische 
Umschau 74(3), 123-130. 
Kreth, K.P., Kovar, K.A., Schwab, M., and Zanger, U.M. (2000). Identification of the human 
cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer 
drugs. Biochem Pharmacol 59(12), 1563-1571. 
Kuypers, K.P., de la Torre, R., Farre, M., Yubero-Lahoz, S., Dziobek, I., Van den Bos, W., et al. 
(2014). No evidence that MDMA-induced enhancement of emotional empathy is related 
to peripheral oxytocin levels or 5-HT1a receptor activation. PLoS One 9(6), e100719. 
Kuypers, K.P.C., de la Torre, R., Farre, M., Xicota, L., de Sousa Fernandes Perna, E.B., 
Theunissen, E.L., et al. (2018). Depressive mood ratings are reduced by MDMA in female 
Reference List 
 
139 
 
polydrug ecstasy users homozygous for the l-allele of the serotonin transporter. Sci Rep 
8(1), 1061. 
Lester, S.J., Baggott, M., Welm, S., Schiller, N.B., Jones, R.T., Foster, E., et al. (2000). 
Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, 
placebo-controlled trial. Ann Intern Med 133(12), 969-973. 
Liechti, M.E. (2014). Effects of MDMA on body temperature in humans. Temperature 1, 179-187. 
Liechti, M.E., Baumann, C., Gamma, A., and Vollenweider, F.X. (2000a). Acute psychological 
effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by 
the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22(5), 513-521. 
Liechti, M.E., Gamma, A., and Vollenweider, F.X. (2001a). Gender differences in the subjective 
effects of MDMA. Psychopharmacology (Berl) 154(2), 161-168. 
Liechti, M.E., Kunz, I., and Kupferschmidt, H. (2005). Acute medical problems due to Ecstasy 
use: case-series of emergency department visits. Swiss Med Wkly 135(43-44), 652-657. 
Liechti, M.E., Saur, M.R., Gamma, A., Hell, D., and Vollenweider, F.X. (2000b). Psychological 
and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) 
antagonist ketanserin in healthy humans. Neuropsychopharmacology 23(4), 396-404. 
Liechti, M.E., and Vollenweider, F.X. (2000a). Acute psychological and physiological effects of 
MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. Eur 
Neuropsychopharmacol 10(4), 289-295. 
Liechti, M.E., and Vollenweider, F.X. (2000b). The serotonin uptake inhibitor citalopram reduces 
acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine 
('Ecstasy') in healthy volunteers. J Psychopharmacol 14(3), 269-274. 
Liechti, M.E., and Vollenweider, F.X. (2001). Which neuroreceptors mediate the subjective effects 
of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 16(8), 
589-598. 
Maharaj, R., Pingitore, A., Menon, K., Kane, P., Wendon, J., and Bernal, W. (2015). Images of the 
month: MDMA-induced acute liver failure and transient abdominal pneumatosis. Am J 
Gastroenterol 110(7), 963. 
Maria, K., Charalampos, T., Vassilakopoulou, D., Stavroula, S., Vasiliki, K., and Nikolaos, D. 
(2012). Frequency Distribution of COMT Polymorphisms in Greek Patients with 
Schizophrenia and Controls: A Study of SNPs rs737865, rs4680, and rs165599. ISRN 
Psychiatry 2012, 651613. 
Meyer-Lindenberg, A., Domes, G., Kirsch, P., and Heinrichs, M. (2011). Oxytocin and vasopressin 
in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 
12(9), 524-538. 
Meyer, M.R., Peters, F.T., and Maurer, H.H. (2008). The role of human hepatic cytochrome P450 
isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its 
enantiomers. Drug Metab Dispos 36(11), 2345-2354. 
Reference List 
 
140 
 
Miller, G.M. (2011). The emerging role of trace amine-associated receptor 1 in the functional 
regulation of monoamine transporters and dopaminergic activity. J Neurochem 116(2), 
164-176. 
Mills, E.M., Banks, M.L., Sprague, J.E., and Finkel, T. (2003). Pharmacology: uncoupling the 
agony from ecstasy. Nature 426(6965), 403-404. 
Mills, E.M., Rusyniak, D.E., and Sprague, J.E. (2004). The role of the sympathetic nervous system 
and uncoupling proteins in the thermogenesis induced by 3,4-
methylenedioxymethamphetamine. J Mol Med 82(12), 787-799. 
Mithoefer, M.C., Feduccia, A.A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., et al. (2019). 
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for 
phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. 
Psychopharmacology (Berl) 236(9), 2735-2745. 
Mithoefer, M.C., Grob, C.S., and Brewerton, T.D. (2016). Novel psychopharmacological therapies 
for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry 3(5), 481-488. 
Mithoefer, M.C., Mithoefer, A.T., Feduccia, A.A., Jerome, L., Wagner, M., Wymer, J., et al. (2018). 
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-
traumatic stress disorder in military veterans, firefighters, and police officers: a 
randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 5(6), 
486-497. 
Molliver, M., O’Hearn, E., Battaglia, G., and De Souza, E. (1986). "Direct intracerebral 
administration of MDA and MDMA does not produce serotonin neurotoxicity", in: Soc 
Neurosci Abstr). 
Monks, T.J., Jones, D.C., Bai, F., and Lau, S.S. (2004). The role of metabolism in 3,4-(+)-
methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) 
toxicity. Ther Drug Monit 26(2), 132-136. 
Nestler, E.J. (2005). Is there a common molecular pathway for addiction? Nat Neurosci 8(11), 
1445-1449. 
Neumann, I.D. (2008). Brain oxytocin: a key regulator of emotional and social behaviours in both 
females and males. J Neuroendocrinol 20(6), 858-865. 
Nichols, D.E. (1986). Differences between the mechanism of action of MDMA, MBDB, and the 
classic hallucinogens. Identification of a new therapeutic class: entactogens. J 
Psychoactive Drugs 18(4), 305-313. 
Nutt, D., King, L.A., Saulsbury, W., and Blakemore, C. (2007). Development of a rational scale to 
assess the harm of drugs of potential misuse. Lancet 369(9566), 1047-1053. 
Nutt, D.J., King, L.A., and Phillips, L.D. (2010). Drug harms in the UK: a multicriteria decision 
analysis. Lancet 376(9752), 1558-1565. 
O'Mathuna, B., Farre, M., Rostami-Hodjegan, A., Yang, J., Cuyas, E., Torrens, M., et al. (2008). 
The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition 
in humans. J Clin Psychopharmacol 28(5), 523-529. 
Reference List 
 
141 
 
Oehen, P., Traber, R., Widmer, V., and Schnyder, U. (2013). A randomized, controlled pilot study 
of MDMA (±3,4-methylenedioxymethamphetamine)-assisted psychotherapy for 
treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol 
27(1), 40-52. 
Pardo-Lozano, R., Farre, M., Yubero-Lahoz, S., O'Mathuna, B., Torrens, M., Mustata, C., et al. 
(2012). Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 
"ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT). PLoS One 
7(10), e47599. 
Parrott, A.C. (2012). MDMA and temperature: a review of the thermal effects of 'Ecstasy' in 
humans. Drug Alcohol Depend 121(1-2), 1-9. 
Parrott, A.C. (2013). MDMA, serotonergic neurotoxicity, and the diverse functional deficits of 
recreational 'Ecstasy' users. Neurosci Biobehav Rev 37(8), 1466-1484. 
Parrott, A.C., Milani, R.M., Parmar, R., and Turner, J.D. (2001). Recreational ecstasy/MDMA and 
other drug users from the UK and Italy: psychiatric symptoms and psychobiological 
problems. Psychopharmacology (Berl) 159(1), 77-82. 
Patel, M.M., Belson, M.G., Longwater, A.B., Olson, K.R., and Miller, M.A. (2005). 
Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. J Emerg Med 29(4), 
451-454. 
Pedersen, N.P., and Blessing, W.W. (2001). Cutaneous vasoconstriction contributes to 
hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious 
rabbits. J Neurosci 21(21), 8648-8654. 
Pizarro, N., Farre, M., Pujadas, M., Peiro, A.M., Roset, P.N., Joglar, J., et al. (2004). 
Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main 
metabolites in human samples including the catechol-type metabolite (3,4-
dihydroxymethamphetamine). Drug Metab Dispos 32(9), 1001-1007. 
Preissner, S.C., Hoffmann, M.F., Preissner, R., Dunkel, M., Gewiess, A., and Preissner, S. (2013). 
Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. 
PLoS One 8(12), e82562. 
Puerta, E., Hervias, I., and Aguirre, N. (2009). On the mechanisms underlying 3,4-
methylenedioxymethamphetamine toxicity: the dilemma of the chicken and the egg. 
Neuropsychobiology 60(3-4), 119-129. 
Ricaurte, G., Bryan, G., Strauss, L., Seiden, L., and Schuster, C. (1985). Hallucinogenic 
amphetamine selectively destroys brain serotonin nerve terminals. Science 229(4717), 
986-988. 
Rietjens, S.J., Hondebrink, L., Westerink, R.H., and Meulenbelt, J. (2012). Pharmacokinetics and 
pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual 
differences due to polymorphisms and drug-drug interactions. Crit Rev Toxicol 42(10), 
854-876. 
Reference List 
 
142 
 
Rosenson, J., Smollin, C., Sporer, K.A., Blanc, P., and Olson, K.R. (2007). Patterns of ecstasy-
associated hyponatremia in California. Ann Emerg Med 49(2), 164-171. 
Roxburgh, A., and Lappin, J. (2019). MDMA-related deaths in Australia 2000 to 2018. Int J Drug 
Policy 76, 102630. 
Rudnick, G., and Wall, S.C. (1992). The molecular mechanism of "ecstasy" [3,4-methylenedioxy-
methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced 
serotonin release. Proc Natl Acad Sci U S A 89(5), 1817-1821. 
Sabol, S.Z., Hu, S., and Hamer, D. (1998). A functional polymorphism in the monoamine oxidase 
A gene promoter. Hum Genet 103(3), 273-279. 
Sachse, C., Brockmoller, J., Bauer, S., and Roots, I. (1997). Cytochrome P450 2D6 variants in a 
Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 
60(2), 284-295. 
Saunders, N., and Walder, P. (1994). Ecstasy. Bilger Zürich. 
Schenk, S., Hely, L., Lake, B., Daniela, E., Gittings, D., and Mash, D.C. (2007). MDMA self-
administration in rats: acquisition, progressive ratio responding and serotonin 
transporter binding. Eur J Neurosci 26(11), 3229-3236. 
Schmid, Y., Hysek, C.M., Simmler, L.D., Crockett, M.J., Quednow, B.B., and Liechti, M.E. (2014). 
Differential effects of MDMA and methylphenidate on social cognition. J 
Psychopharmacol 28, 847-856. 
Schmidt, A., Muller, F., Dolder, P.C., Schmid, Y., Zanchi, D., Egloff, L., et al. (2018). Acute Effects 
of Methylphenidate, Modafinil, and MDMA on Negative Emotion Processing. Int J 
Neuropsychopharmacol 21(4), 345-354. 
Schwartz, R.H., and Miller, N.S. (1997). MDMA (Ecstasy) and the Rave: A Review. 
Segura, M., Farre, M., Pichini, S., Peiro, A.M., Roset, P.N., Ramirez, A., et al. (2005). Contribution 
of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in 
humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet 44(6), 649-
660. 
Seibert, J., Hysek, C.M., Penno, C.A., Schmid, Y., Kratschmar, D.V., Liechti, M.E., et al. (2014). 
Acute effects of 3,4-methylenedioxymethamphetamine and methylphenidate on 
circulating steroid levels in healthy subjects. Neuroendocrinology 100, 17-25. 
Shulgin, A.T. (1986). The background and chemistry of MDMA. J Psychoactive Drugs 18(4), 291-
304. 
Simmler, L., Buser, T., Donzelli, M., Schramm, Y., Dieu, L.H., Huwyler, J., et al. (2013). 
Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168(2), 
458-470. 
Simmler, L.D., Buchy, D., Chaboz, S., Hoener, M.C., and Liechti, M.E. (2016). In vitro 
characterization of psychoactive substances at rat, mouse, and human trace amine-
associated receptor 1 J Pharmacol Exp Ther 357, 134-144. 
Reference List 
 
143 
 
Sprague, J.E., Banks, M.L., Cook, V.J., and Mills, E.M. (2003). Hypothalamic-pituitary-thyroid 
axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-
methylenedioxymethamphetamine (Ecstasy). J Pharmacol Exp Ther 305(1), 159-166. 
Sprague, J.E., Brutcher, R.E., Mills, E.M., Caden, D., and Rusyniak, D.E. (2004). Attenuation of 
3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with 
alpha1- plus beta3-adrenoreceptor antagonists. Br J Pharmacol 142(4), 667-670. 
Steuer, A.E., Boxler, M.I., Stock, L., and Kraemer, T. (2016). Inhibition potential of 3,4-
methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro 
monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin 
and dopamine. Toxicol Lett 243, 48-55. 
Studerus, E., Gamma, A., Kometer, M., and Vollenweider, F.X. (2012). Prediction of psilocybin 
response in healthy volunteers. PLoS One 7(2), e30800. 
Thompson, M.R., Callaghan, P.D., Hunt, G.E., Cornish, J.L., and McGregor, I.S. (2007). A role for 
oxytocin and 5-HT1A receptors in the prosocial effects of 3,4 
methylenedioxymethamphetamine ("ecstasy"). Neuroscience 146(2), 509-514. 
United Nations Office On Drugs And Crime, (2019). World Drug Report 2019. United Nations 
publication, Sales No. E.19.XI.8. 
Verma, D., Chakraborti, B., Karmakar, A., Bandyopadhyay, T., Singh, A.S., Sinha, S., et al. (2014). 
Sexual dimorphic effect in the genetic association of monoamine oxidase A (MAOA) 
markers with autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry 
50, 11-20. 
Vizeli, P., and Liechti, M.E. (2017). Safety pharmacology of acute MDMA administration in 
healthy subjects. J Psychopharmacol 31(5), 576-588. 
Wagner, D., Becker, B., Koester, P., Gouzoulis-Mayfrank, E., and Daumann, J. (2013). A 
prospective study of learning, memory, and executive function in new MDMA users. 
Addiction 108(1), 136-145. 
Wardle, M.C., and de Wit, H. (2014). MDMA alters emotional processing and facilitates positive 
social interaction. Psychopharmacology (Berl) 231(21), 4219-4229. 
Wardle, M.C., Yang, A., and de Wit, H. (2012). Effect of d-amphetamine on post-error slowing in 
healthy volunteers. Psychopharmacology (Berl) 220(1), 109-115. 
Wolff, K., Tsapakis, E.M., Pariante, C.M., Kerwin, R.W., Forsling, M.L., and Aitchison, K.J. (2012). 
Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption. J 
Psychopharmacol 26(3), 419-428. 
Yang, J., Jamei, M., Heydari, A., Yeo, K.R., de la Torre, R., Farre, M., et al. (2006). Implications 
of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of 
MDMA. J Psychopharmacol 20(6), 842-849. 
Yubero-Lahoz, S., Pardo, R., Farre, M., Mathuna, B.O., Torrens, M., Mustata, C., et al. (2012). 
Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine 
Reference List 
 
144 
 
(MDMA, ecstasy) administration using caffeine as a probe drug. Drug Metab 
Pharmacokinet 27(6), 605-613. 
 145 
 
 
